Study: Single, High-dose Erythropoietin Given 2 Days Pre-op Reduces Need for Transfused Blood

In non-cardiac and cardiac surgical procedures, anemia increases operative mortality and morbidity. More blood transfusions might be required by anemic surgical patients, raising the risk of transfusion-related complications and increasing costs. For those reasons, optimizing patient readiness by correcting anemia prior to surgery is an important clinical goal. A simple new protocol has been proposed that helps correcting anemia using a single, high dose of recombinant human erythropoietin (HRE) administered only two days prior to surgery. The results of a randomized study will be presented by Luca Weltert, MD, Cardiac Surgery Department of the European Hospital in Rome, during the Plenary Scientific Session of the 93rd AATS Annual Meeting in Minneapolis. HRE, a red blood cell growth factor, can offset anemia, but previous protocols required that HRE must be given many days or even weeks before surgery following a complicated dosage regimen. Practically, patients often do not have that much time for preparation, and sometimes surgery must be delayed, increasing hospital costs.

In this single-blind randomized study of 600 patients presenting for heart surgery, 300 patients received a single dose of HRE 80,000 UI as a bolus two days prior to surgery and 300 patients served as controls. The results showed that prior administration of HRE reduced transfusion requirements by about one third, from a mean of 1.12 blood units per patient to 0.39 blood units per patient (p<0.001). In the control group, 39% of patients required a transfusion, compared to 17% of those who received HRE. Mean hemoglobin levels on postop day 4 were significantly higher in the HRE group (9.02 vs. 10.21 g/dl, p=0.02). No differences between groups were found for mortality or adverse events.

The HRE protocol also resulted in cost savings, according to Dr. Weltert. Taking into account the costs of HRE, the cost of a blood transfusion (blood and labor costs), and the savings from avoiding blood transfusions, Dr. Weltert found that the HRE protocol was cost-effective.

"HRE therapy remains a viable, yet underused option, a milestone in the 'bloodless story.' In the past its role was predominantly in association with preoperative autologous blood donation, while in the present its role has to be focused on the management of perioperative anemia," says Dr. Weltert.

Source-Eurekalert